Back to the main directory
Company Analysis / Equity
- ARLZ: NDA for YOSPRALA® Submitted; Approval Likely in the Fourth Quarter of 2016… by Zacks
- ARLZ: Third Times a Charm! FDA Approves YOSPRALA®; Will Launch the First Week of October 2016 by Zacks
- ARLZ: YOSPRALA® PDUFA Date is September 14, 2016 by Zacks
- ARWR: Clinical hold on Heparc-2004 is probably temporary, Collaborations with Amgen announced, Phase I/II ARC-521 initiated by Zacks
- ARWR: Strategic shift to subQ and extrahepatic programs, Collaborations with Amgen announced by Zacks
- Another strong quarter of financial performance by Zacks
- Expecting strong financials for fiscal 4Q12, raising price target to $0.25 by Zacks
- Record financials reported, price target achieved by Zacks
- Unique anti-counterfeiting technology, and high growth potential---- Outperform rating by Zacks
- Unique anti-counterfeiting technology, and record current quarter financials---- maintaining an Outperform rating by Zacks
- Unique anti-counterfeiting technology, and record current quarter financials----maintaining an Outperform rating by Zacks
- Unique anti-counterfeiting technology, initiating with an Outperform rating by Zacks
- Unique anti-counterfeiting technology, maintaining an Outperform rating by Zacks
- ARWR: ARC-520 is still alive, Strong balance sheet, new clinical candidate nominated, on track initiate Phase IIb of ARC-520 maintaining Outperform by Zacks
- Balance sheet boosted by recent financing, on track to advance ARC-520 into Phase IIa maintaining Outperform by Zacks
- ARWR: New clinical candidate nominated, on track to complete Phase II a and initiate Phase IIb of ARC-520 maintaining Outperform by Zacks
- ARWR: New data presented for ARC-520, multiple Phase IIb studies initiated, new candidate nominated--positive by Zacks
- ARWR: New data presented for ARC-520, three Phase IIb studies initiated, new candidate nominated--- maintaining Buy by Zacks
- ARWR: Phase I/II ARC-521 initiated, New data presented for ARC-520, multiple Phase IIb studies initiated, new candidate nominated by Zacks
- ARWR: Strong balance sheet, ARC-520 is still alive, on track initiate Phase IIb of ARC- 520, ARC-AAT to start Phase I soon maintaining Outperform by Zacks
- ARWR: to initiate Phase IIb of ARC-520 in 1H15, ARC-AAT to start Phase I soon maintaining Outperform by Zacks
- Balance sheet remains strong, on track to advance ARC-520 maintaining Outperform by Zacks
- ARWR: Phase I of ARC-520 completed, on track to advance ARC-520 into Phase IIa maintaining Outperform by Zacks
- ATOS: A pure play biopharma after sale of its diagnostics business, two Phase II clinical programs Buy by Zacks
- ATOS: A pure play biopharma after sale of its diagnostics business, two Phase II clinical trial will be initiated soon Buy by Zacks
- ARLZ: PDUFA Date for YOSPRALA® Set For September 14, 2016 by Zacks
- ARLZ: YOSPRALA™ Hits the Market and the Acquisition of Toprol-XL® is Complete… by Zacks
- ARWR: Balance sheet remains strong, Strategic shift to subQ and extra-hepatic programs, Collaborations with Amgen announced by Zacks
- ARWR: Collaborations with Amgen announced, Phase I/II ARC-521 initiated, New data presented for ARC-520, multiple Phase IIb studies initiated, new candidate nominated by Zacks
- Another strong quarter of financial performance by Zacks
- Businesses continue to grow, revenue growth will resume in second half of the fiscal year---Neutral by Zacks
- First fiscal quarter financials were disappointing by Zacks
- Record revenue achieved in fiscal 1Q12 by Zacks
- Unique anti-counterfeiting technology, and high growth potential----Outperform rating by Zacks
- Unique anti-counterfeiting technology, and record current quarter financials---- maintaining an Outperform rating by Zacks
- Unique anti-counterfeiting technology, initiating with an Outperform rating by Zacks
- Unique anti-counterfeiting technology, maintaining an Outperform rating by Zacks
- ARWR: ARC-520 is a viable drug for HBV, three Phase IIb studies initiated, new candidate nominated--- maintaining Buy by Zacks
- ARWR: Acquisition of Novartis RNAi assets significantly expands and complements the company s current RNAi estate maintaining Outperform by Zacks
- ARWR: Full Phase IIa data will be announced in 3Q, three Phase IIb studies initiated--- maintaining Buy by Zacks
- ARWR: New data presented for ARC-520, multiple Phase IIb studies initiated, new candidate nominated--- maintaining Buy by Zacks
- ARWR: New data presented for ARC-520, three Phase IIb studies initiated, new candidate nominated--- maintaining Buy by Zacks
- ARWR: On track to complete Phase II a and initiate Phase IIb of ARC-520 maintaining Outperform by Zacks
- ARWR: Phase IIb cleared to start; Full Phase IIa data will be announced in 3Q, Acquisition of Novartis RNAi assets significantly expands and complements the company s current RNAi estate maintaining Buy by Zacks
- ARWR: Strong balance sheet, New clinical candidate nominated, on track to complete Phase II a and initiate Phase IIb of ARC-520 maintaining Outperform by Zacks
- ARWR: expects to initiate Phase IIa study of ARC-520 in Hong Kong soon maintaining Outperform by Zacks
- Balance sheet boosted by recent financing, on track to advance ARC-520 into Phase IIa maintaining Outperform by Zacks
- ATOS: A pure play biopharma after sale of its diagnostics business by Zacks
- ATOS: A pure play biopharma after sale of its diagnostics business, two Phase II clinical programs, and one new clinical program initiated. by Zacks
- ATOS: ATOS enters therapeutic market via acquisition, significant revenue growth from pharmacogenomics testing in 1Q15, which convinces us revenue growth will accelerate in the coming quarters Buy by Zacks